AIM
CBMG

Acrospire Investment Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Acrospire Investment Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-300
Closed -$4K – 2510
2016
Q3 		$4K Buy
+300
New +$4.26K ﹤0.01% 1864

Other funds holding CBMG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 28.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acrospire Investment Management's CBMG Position: Q4 2016 in Review

Acrospire Investment Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2016, closing a stake of 300 shares — an estimated $4K sold.

Acrospire Investment Management first reported a position in CBMG in Q3 2016 and held it in 1 quarter. The position peaked at $4K in Q3 2016. 38 funds tracked by Wall St. Rank hold CBMG as of Q4 2016.

  • Acrospire Investment Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 300 Cellular Biomedicine Group, Inc. shares in Q4 2016, an estimated $4K.
  • Acrospire Investment Management first reported a position in Cellular Biomedicine Group, Inc. in Q3 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Cellular Biomedicine Group, Inc. position peaked at $4K in Q3 2016.
  • 38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.